[CONGENITAL PSEUDOEROSION OF THE CERVIX UTERI AND ITS OUTCOME].

H. Hamperl

1965-01-26

Archiv für Gynäkologie

Abstract:

What problem does this paper attempt to address?

ALG9-CDG: New Clinical Case and Review of the Literature

Kellie Davis,Duncan Webster,Chris Smith,Sheryl Jackson,David Sinasac,Lorne Seargeant,Xing-Chang Wei,Patrick Ferreira,Julian Midgley,Yolanda Foster,Xueli Li,Miao He,Walla Al-Hertani

DOI: https://doi.org/10.1016/j.ymgmr.2017.08.004

IF: 2.082

2017-01-01

Molecular Genetics and Metabolism Reports

Abstract:Congenital disorders of glycosylation (CDG) are a group of metabolic diseases resulting from defects in glycan synthesis or processing. The number of subgroups and their phenotypic spectrums continue to expand with most related to deficiencies of N-glycosylation. ALG9-CDG (previously CDG-IL) is the result of a mutation in ALG9. This gene encodes the enzyme alpha-1,2-mannosyltransferase. To date, a total of 10 patients from 6 different families have been reported with one of four ALG9 mutations. Seven of these patients had a similar phenotype with failure to thrive, dysmorphic features, seizures, hepatic and/or renal cysts; the other three patients died in utero from a lethal skeletal dysplasia. This report describes an additional patient with ALG9-CDG who has a milder phenotype. This patient is a term female born to Caucasian, Canadian, non-consanguineous parents of Scottish decent. Prenatally, dysmorphic features, numerous renal cysts and minor cardiac malformations were detected. Post-natally, dysmorphic features included shallow orbits, micrognathia, hypoplastic nipples, talipes equinovarus, lipodystrophy and cutis marmorata. She developed failure to thrive and seizures. The metabolic work-up included analysis of a transferrin isoelectric focusing, which showed a type 1 pattern. This was confirmed by glycan profiling, which identified ahomozygous mutation in ALG9, c.860A > G (p.Tyr287Cys) (NM_1234567890). This had been previously published as a pathogenic mutation in two Canadian patients. Our goal is to contribute to the growing body of knowledge for this disorder by describing the phenotypic spectrum and providing further insight on prognosis.
ALG13 X‐linked intellectual disability: New variants, glycosylation analysis, and expanded phenotypes

Hind Alsharhan,Miao He,Andrew C. Edmondson,Earnest J. P. Daniel,Jie Chen,Tyhiesia Donald,Somayeh Bakhtiari,David J. Amor,Elizabeth A. Jones,Grace Vassallo,Marie Vincent,Benjamin Cogné,Wallid Deb,Arend H. Werners,Sheng C. Jin,Kaya Bilguvar,John Christodoulou,Richard I. Webster,Katherine R. Yearwood,Bobby G. Ng,Hudson H. Freeze,Michael C. Kruer,Dong Li,Kimiyo M. Raymond,Elizabeth J. Bhoj,Andrew K. Sobering

DOI: https://doi.org/10.1002/jimd.12378

IF: 4.7501

2021-03-26

Journal of Inherited Metabolic Disease

Abstract:Pathogenic variants in ALG13 (ALG13 UDP‐N‐acetylglucosaminyltransferase subunit) cause an X‐linked congenital disorder of glycosylation (ALG13‐CDG) where individuals have variable clinical phenotypes that include developmental delay, intellectual disability, infantile spasms, and epileptic encephalopathy. Girls with a recurrent de novo c.3013C>T; p.(Asn107Ser) variant have normal transferrin glycosylation. Using a highly sensitive, semi‐quantitative flow injection‐electrospray ionization‐quadrupole time‐of‐flight mass spectrometry (ESI‐QTOF/MS) N‐glycan assay, we report subtle abnormalities in N‐glycans that normally account for < 0.3% of the total plasma glycans that may increase up to 0.5% in females with the p.(Asn107Ser) variant. Among our 11 unrelated ALG13‐CDG individuals, one male had abnormal serum transferrin glycosylation. We describe seven previously unreported subjects including three novel variants in ALG13 and report a milder neurodevelopmental course. We also summarize the molecular, biochemical, and clinical data for the 53 previously reported ALG13‐CDG individuals. We provide evidence that ALG13 pathogenic variants may mildly alter N‐linked protein glycosylation in both female and male subjects, but the underlying mechanism remains unclear.

genetics & heredity,endocrinology & metabolism,medicine, research & experimental
Identification of two novel variants in ALG11 causing congenital disorder of glycosylation

Peiwei Zhao,Xiankai Zhang,Zhengrong Duan,Chunhui Wan,Lei Zhang,Sukun Luo,Hongmin Zhu,Xuelian He

DOI: https://doi.org/10.1016/j.seizure.2024.07.020

IF: 3.414

Seizure

Abstract:Background: Congenital disorders of glycosylation (CDG) represent a heterogeneous group of rare inherited metabolic disorders due to abnormalities in protein or lipid glycosylation pathways, affecting multiple systems, and frequently being accompanied by neurological symptoms. ALG11-CDG, also known as CDG-1p, arises from a deficiency in a specific mannosyltransferase encoded by the ALG11 gene. To date, only 17 cases have been documented, and these patients have prominent clinical phenotypes, including seizures, developmental delay, and microcephaly. Methods: We describe a novel case of a four-month-old boy from a Chinese family exhibiting developmental delay, seizures, and microcephaly. Trio whole-exome sequencing (WES) and subsequent Sanger sequencing were employed to identify the potential genetic cause, and functional study was performed to evaluate the pathogenicity of genetic variant identified. Results: Trio WES unveiled novel compound heterozygous variants: c.1307G>T (p.G436V) and c.1403G>A (p.R468H) within exon 4 of the ALG11 gene, inherited from the father and mother, respectively. Subsequent in vitro functional analysis revealed decreased stability of the mutant protein and concurrent hypoglycosylation of GP130, a hyperglycosylated protein. Conclusions: Our findings not only expand the clinical and variant spectrum of ALG11-CDG, but also emphasize the importance of WES as a first-tier genetic test in determining the molecular diagnosis.
Targeted Sequencing and RNA Assay Reveal a Noncanonical JAG1 Splicing Variant Causing Alagille Syndrome.

Yiyao Chen,Xueli Liu,Songchang Chen,Junyu Zhang,Chenming Xu

DOI: https://doi.org/10.3389/fgene.2019.01363

IF: 3.7

2020-01-01

Frontiers in Genetics

Abstract:Alagille syndrome (ALGS), as known as congenital arteriohepatic dysplasia, is a rare autosomal dominant multi-systemic disorder. Mutations in JAG1 or more rarely NOTCH2 have been reported as the cause of ALGS. In this study, a 5-year old girl with typical ALGS feature and her pregnant mother came to our reproductive genetics clinic for counseling. We aimed to clarify the genetic diagnosis and provide prenatal genetic diagnosis for the pregnant. Next generation sequencing (NGS)-based multigene panel was used to identify pathogenic variant of the proband. Then the candidate variant was verified by using Sanger sequencing. RNA assay was performed to clarify splicing effect of the candidate variant. Amniocentesis, karyotyping, and Sanger sequencing were performed for prenatal testing. We found a novel de novo noncanonical JAG1 splicing variant (c.2917-8C > A) in the proband. Peripheral blood RNA assay suggested that the mutant transcript might escape nonsense-mediated messenger RNA (mRNA) decay (NMD) and encode a C-terminal truncated protein. Information of the variant has resulted in a successful prenatal diagnosis of the fetus. Our results clarified the genetic diagnosis of an ALGS patient and ensured utility of prenatal genetic testing.
Application of the change in partition coefficient with pH to the structure determination of alkyl substituted guanosines.

P. Moore,M. Koreeda*

DOI: https://doi.org/10.1016/0006-291X(76)90729-4

1976-11-22

Abstract:
A case of fatal Type I congenital disorders of glycosylation (CDG I) associated with low dehydrodolichol diphosphate synthase (DHDDS) activity

S. Sabry,S. Vuillaumier-Barrot,E. Mintet,M. Fasseu,V. Valayannopoulos,D. Héron,N. Dorison,C. Mignot,N. Seta,I. Chantret,T. Dupré,S. E. H. Moore

DOI: https://doi.org/10.1186/s13023-016-0468-1

2016-06-24

Orphanet Journal of Rare Diseases

Abstract:BackgroundType I congenital disorders of glycosylation (CDG-I) are mostly complex multisystemic diseases associated with hypoglycosylated serum glycoproteins. A subgroup harbour mutations in genes necessary for the biosynthesis of the dolichol-linked oligosaccharide (DLO) precursor that is essential for protein N-glycosylation. Here, our objective was to identify the molecular origins of disease in such a CDG-Ix patient presenting with axial hypotonia, peripheral hypertonia, enlarged liver, micropenis, cryptorchidism and sensorineural deafness associated with hypo glycosylated serum glycoproteins.ResultsTargeted sequencing of DNA revealed a splice site mutation in intron 5 and a non-sense mutation in exon 4 of the dehydrodolichol diphosphate synthase gene (DHDDS). Skin biopsy fibroblasts derived from the patient revealed ~20 % residual DHDDS mRNA, ~35 % residual DHDDS activity, reduced dolichol-phosphate, truncated DLO and N-glycans, and an increased ratio of [2-3H]mannose labeled glycoprotein to [2-3H]mannose labeled DLO. Predicted truncated DHDDS transcripts did not complement rer2-deficient yeast. SiRNA-mediated down-regulation of DHDDS in human hepatocellular carcinoma HepG2 cells largely mirrored the biochemical phenotype of cells from the patient. The patient also harboured the homozygous ALG6(F304S) variant, which does not cause CDG but has been reported to be more frequent in PMM2-CDG patients with severe/fatal disease than in those with moderate presentations. WES did not reveal other strong candidate causal genes.ConclusionsWe describe a patient presenting with severe multisystem disease associated with DHDDS deficiency. As retinitis pigmentosa is the only clinical sign in previously reported cases, this report broadens the spectrum of phenotypes associated with this condition.

genetics & heredity,medicine, research & experimental
Neurobehavioral changes following bilateral infarct in the caudate nuclei: a case report with pathological analysis

G. Rodier,C. Tranchant,M. Mohr,J. Warter

DOI: https://doi.org/10.1016/0022-510X(94)90276-3

1994-11-01

Journal of Neurological Sciences

Abstract:
Case report: Novel genotype of ALG2-CDG and confirmation of the heptasaccharide glycan (NeuAc-Gal-GlcNAc-Man2-GlcNAc2) as a specific diagnostic biomarker

Ivan Martínez Duncker,Denisse Mata-Salgado,Ibrahim Shammas,Wasantha Ranatunga,Earnest James Paul Daniel,Mario E. Cruz Muñoz,Melania Abreu,Héctor Mora-Montes,Miao He,Eva Morava,Gildardo Zafra de la Rosa

DOI: https://doi.org/10.3389/fgene.2024.1363558

IF: 3.7

2024-05-06

Frontiers in Genetics

Abstract:This report outlines the case of a child affected by a type of congenital disorder of glycosylation (CDG) known as ALG2-CDG (OMIM 607906), presenting as a congenital myasthenic syndrome (CMS) caused by variants identified in ALG2 , which encodes an α1,3-mannosyltransferase (EC 2.4.1.132) involved in the early steps of N-glycosylation. To date, fourteen cases of ALG2-CDG have been documented worldwide. From birth, the child experienced perinatal asphyxia, muscular weakness, feeding difficulties linked to an absence of the sucking reflex, congenital hip dislocation, and hypotonia. Over time, additional complications emerged, such as inspiratory stridor, gastroesophageal reflux, low intake, recurrent seizures, respiratory infections, an inability to maintain the head upright, and a global developmental delay. Whole genome sequencing (WGS) revealed the presence of two ALG2 variants in compound heterozygosity: a novel variant c.1055_1056delinsTGA p.(Ser352Leufs*3) and a variant of uncertain significance (VUS) c.964C>A p.(Pro322Thr). Additional studies, including determination of carbohydrate-deficient transferrin (CDT) revealed a mild type I CDG pattern and the presence of an abnormal transferrin glycoform containing a linear heptasaccharide consisting of one sialic acid, one galactose, one N-acetyl-glucosamine, two mannoses and two N-acetylglucosamines (NeuAc-Gal-GlcNAc-Man2-GlcNAc2), ALG2-CDG diagnostic biomarker, confirming the pathogenicity of these variants.

genetics & heredity
Dysregulated proteome and N‐glycoproteome in ALG1‐deficient fibroblasts

Rohit Budhraja,Neha Joshi,Silvia Radenkovic,Tamas Kozicz,Eva Morava,Akhilesh Pandey

DOI: https://doi.org/10.1002/pmic.202400012

2024-03-14

PROTEOMICS

Abstract:Asparagine‐linked glycosylation 1 protein is a β‐1,4‐mannosyltransferase, is encoded by the ALG1 gene, which catalyzes the first step of mannosylation in N‐glycosylation. Pathogenic variants in ALG1 cause a rare autosomal recessive disorder termed as ALG1‐CDG. We performed a quantitative proteomics and N‐glycoproteomics study in fibroblasts derived from patients with one homozygous and two compound heterozygous pathogenic variants in ALG1. Several proteins that exhibited significant upregulation included insulin‐like growth factor II and pleckstrin, whereas hyaluronan and proteoglycan link protein 1 was downregulated. These proteins are crucial for cell growth, survival and differentiation. Additionally, we observed a decrease in the expression of mitochondrial proteins and an increase in autophagy‐related proteins, suggesting mitochondrial and cellular stress. N‐glycoproteomics revealed the reduction in high‐mannose and complex/hybrid glycopeptides derived from numerous proteins in patients explaining that defect in ALG1 has broad effects on glycosylation. Further, we detected an increase in several short oligosaccharides, including chitobiose (HexNAc2) trisaccharides (Hex‐HexNAc2) and novel tetrasaccharides (NeuAc‐Hex‐HexNAc2) derived from essential proteins including LAMP1, CD44 and integrin. These changes in glycosylation were observed in all patients irrespective of their gene variants. Overall, our findings not only provide novel molecular insights into understanding ALG1‐CDG but also offer short oligosaccharide‐bearing peptides as potential biomarkers.

biochemistry & molecular biology,biochemical research methods
COG6-CDG: Two Novel Variants and Milder Phenotype in a Chinese Patient

Xue-Yuan Zhang,Jing Zhang,Yi Lu

DOI: https://doi.org/10.1155/2024/9857442

2024-02-12

Human Mutation

Abstract:Here, we present a Han Chinese pediatric girl highly suspected of congenial disorder of glycosylation type IIL (CDG2L; OMIM#614576). Her clinical symptoms include transferase abnormal, liver cirrhosis, hemogram, coagulopathy, growth retardation, intellectual disability, frequent infections, and enamel hypoplasia. Trio-genome sequencing identified in COG6 a paternal variant c.1672C>T (p.Gln558Ter) and a maternal variant c.153+392A>G (p.?). Reverse transcription-polymerase chain reaction (RT-PCR) using mRNA isolated from peripheral blood confirmed the pathogenicity of both variants. The paternal variant resulted in nonsense-mediated mRNA decay. The maternal variant generated two aberrant COG6 transcripts with 154 bp overlap and was predicted to result in a frameshift at the same position, leading to generation of a premature termination codon. They might result in synthesis of a truncated form of COG6. Thus, the patient was genetically diagnosed.

genetics & heredity
Two compound heterozygous variants in the CLN8 gene are responsible for neuronal cereidolipofuscinoses disorder in a child: a case report

Federico Baltar,Camila Simoes,Francisco Garagorry,Martín Graña,Soledad Rodríguez,María Haydée Aunchayna,Alejandra Tapié,Alfredo Cerisola,Gabriel González,Hugo Naya,Lucía Spangenberg,Víctor Raggio

DOI: https://doi.org/10.3389/fped.2024.1379254

IF: 3.569

2024-05-02

Frontiers in Pediatrics

Abstract:Background: Neuronal Ceroid Lipofuscinosis (NCL) disorders, recognized as the primary cause of childhood dementia globally, constitute a spectrum of genetic abnormalities. CLN8, a subtype within NCL, is characterized by cognitive decline, motor impairment, and visual deterioration. This study focuses on an atypical case with congenital onset and a remarkably slow disease progression. Methods: Whole-genome sequencing at 30× coverage was employed as part of a national genomics program to investigate the genetic underpinnings of rare diseases. This genomic approach aimed to challenge established classifications (vLINCL and EPMR) and explore the presence of a continuous phenotypic spectrum associated with CLN8 . Results: The whole-genome sequencing revealed two novel likely pathogenic mutations in the CLN8 gene on chromosome 8p23.3. These mutations were not previously associated with CLN8-related NCL. Contrary to established classifications (vLINCL and EPMR), our findings suggest a continuous phenotypic spectrum associated with CLN8. Pathological subcellular markers further validated the genomic insights. Discussion: The identification of two previously undescribed likely pathogenic CLN8 gene mutations challenges traditional classifications and highlights a more nuanced phenotypic spectrum associated with CLN8. Our findings underscore the significance of genetic modifiers and interactions with unrelated genes in shaping variable phenotypic outcomes. The inclusion of pathological subcellular markers further strengthens the validity of our genomic insights. This research enhances our understanding of CLN8 disorders, emphasizing the need for comprehensive genomic analyses to elucidate the complexity of phenotypic presentations and guide tailored therapeutic strategies. The identification of new likely pathogenic mutations underscores the dynamic nature of CLN8 -related NCL and the importance of individualized approaches to patient management.

pediatrics
The phenotypic spectrum of X-linked, infantile onset ALG13-related developmental and epileptic encephalopathy

Alexandre N Datta,Nadia Bahi-Buisson,Thierry Bienvenu,Sarah E Buerki,Fiona Gardiner,J Helen Cross,Bénédicte Heron,Anna Kaminska,Christian M Korff,Anne Lepine,Gaetan Lesca,Amy McTague,Heather C Mefford,Cyrill Mignot,Matthieu Milh,Amélie Piton,Ronit M Pressler,Susanne Ruf,Lynette G Sadleir,Anne de Saint Martin,Koen Van Gassen,Nienke E Verbeek,Dorothée Ville,Nathalie Villeneuve,Pia Zacher,Ingrid E Scheffer,Johannes R Lemke

DOI: https://doi.org/10.1111/epi.16761

IF: 6.74

Epilepsia

Abstract:Objective: Asparagine-linked glycosylation 13 (ALG13) deficiencies have been repeatedly described in the literature with the clinical phenotype of a developmental and epileptic encephalopathy (DEE). Most cases were females carrying the recurrent ALG13 de novo variant, p.(Asn107Ser), with normal transferrin electrophoresis. Methods: We delineate the phenotypic spectrum of 38 individuals, 37 girls and one boy, 16 of them novel and 22 published, with the most common pathogenic ALG13 variant p.(Asn107Ser) and additionally report the phenotype of three individuals carrying other likely pathogenic ALG13 variants. Results: The phenotypic spectrum often comprised pharmacoresistant epilepsy with epileptic spasms, mostly with onset within the first 6 months of life and with spasm persistence in one-half of the cases. Tonic seizures were the most prevalent additional seizure type. Electroencephalography showed hypsarrhythmia and at a later stage of the disease in one-third of all cases paroxysms of fast activity with electrodecrement. ALG13-related DEE was usually associated with severe to profound developmental delay; ambulation was acquired by one-third of the cases, whereas purposeful hand use was sparse or completely absent. Hand stereotypies and dyskinetic movements including dystonia or choreoathetosis were relatively frequent. Verbal communication skills were absent or poor, and eye contact and pursuit were often impaired. Significance: X-linked ALG13-related DEE usually manifests as West syndrome with severe to profound developmental delay. It is predominantly caused by the recurrent de novo missense variant p.(Asn107Ser). Comprehensive functional studies will be able to prove or disprove an association with congenital disorder of glycosylation.
Normal transferrin glycosylation does not rule out severe ALG1 deficiency

Inez Bosnyak,Mustafa Sadek,Wasantha Ranatunga,Tamas Kozicz,Eva Morava

DOI: https://doi.org/10.1002/jmd2.12415

2024-04-16

JIMD Reports

Abstract:Abstract ALG1‐CDG is a rare, clinically variable metabolic disease, caused by the defect of adding the first mannose (Man) to N‐acetylglucosamine (GlcNAc 2 )‐pyrophosphate (PP)‐dolichol to the growing oligosaccharide chain, resulting in impaired N‐glycosylation of proteins. N‐glycosylation has a key role in functionality, stability, and half‐life of most proteins. Therefore, congenital defects of glycosylation typically are multisystem disorders. Here we report a 3‐year‐old patient with severe neurological, cardiovascular, respiratory, musculoskeletal and gastrointestinal symptoms. ALG1‐CDG was suggested based on exome sequencing and Western blot analysis. Despite her severe clinical manifestations and genetic diagnosis, serum transferrin glycoform analysis was normal. Western blot analysis of highly glycosylated proteins in fibroblasts revealed decreased intercellular adhesion molecule 1 (ICAM1), but normal lysosomal associated membrane protein 1 and 2 (LAMP1 and LAMP2) expression levels. Glycoproteomics in fibroblasts showed the presence of the abnormal tetrasacharide. Reviewing the literature, we found 86 reported ALG1‐CDG patients, but only one with normal transferrin analysis. Based on our results we would like to highlight the importance of multiple approaches in diagnosing ALG1‐CDG, as normal serum transferrin glycosylation or other biomarkers with normal expression levels can occur.
Deficient glycan extension and endoplasmic reticulum stresses in ALG3‐CDG

Earnest J. P. Daniel,Andrew C. Edmondson,Yair Argon,Hind Alsharhan,Christina Lam,Hudson H. Freeze,Miao He

DOI: https://doi.org/10.1002/jimd.12739

IF: 4.7501

2024-04-12

Journal of Inherited Metabolic Disease

Abstract:ALG3‐CDG is a rare congenital disorder of glycosylation (CDG) with a clinical phenotype that includes neurological manifestations, transaminitis, and frequent infections. The ALG3 enzyme catalyzes the first step of endoplasmic reticulum (ER) luminal glycan extension by adding mannose from Dol‐P‐Man to Dol‐PP‐Man5GlcNAc2 (Man5) forming Dol‐PP‐Man6. Such glycan extension is the first and fastest cellular response to ER stress, which is deficient in ALG3‐CDG. In this study, we provide evidence that the unfolded protein response (UPR) and ER‐associated degradation activities are increased in ALG3‐CDG patient‐derived cultured skin fibroblasts and there is constitutive activation of UPR mediated by the IRE1‐α pathway. In addition, we show that N‐linked Man3‐4 glycans are increased in cellular glycoproteins and secreted plasma glycoproteins with hepatic or non‐hepatic origin. We found that like other CDGs such as ALG1‐ or PMM2‐CDG, in transferrin, the assembling intermediate Man5 in ALG3‐CDG, are likely further processed into a distinct glycan, NeuAc1Gal1GlcNAc1Man3GlcNAc2, probably by Golgi mannosidases and glycosyltransferases. We predict it to be a mono‐antennary glycan with the same molecular weight as the truncated glycan described in MGAT2‐CDG. In summary, this study elucidates multiple previously unrecognized biochemical consequences of the glycan extension deficiency in ALG3‐CDG which will have important implications in the pathogenesis of CDG.

genetics & heredity,endocrinology & metabolism,medicine, research & experimental
X-Ray Lasers: Picosecond Soft X-Ray Laser Pulses from an Injection-Seeded Plasma Amplifier

Y. Wang,M. Berrill,F. Pedaci,M. Shakya,S. Gilbertson,Z. Chang,Eduardo Granados,B. Luther,M. Larotonda,D. Alessi,J. Rocca

Abstract:
Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation

Christina Lam,Carlos Ferreira,Donna Krasnewich,Camilo Toro,Lea Latham,Wadih M. Zein,Tanya Lehky,Carmen Brewer,Eva H. Baker,Audrey Thurm,Cristan A. Farmer,Sergio D. Rosenzweig,Jonathan J. Lyons,John M. Schreiber,Andrea Gropman,Shilpa Lingala,Marc G. Ghany,Beth Solomon,Ellen Macnamara,Mariska Davids,Constantine A. Stratakis,Virginia Kimonis,William A. Gahl,Lynne Wolfe

DOI: https://doi.org/10.1038/gim.2016.75

IF: 8.864

2017-02-01

Genetics in Medicine

Abstract:Purpose:The cytosolic enzyme N-glycanase 1, encoded by NGLY1, catalyzes cleavage of the β-aspartyl glycosylamine bond of N-linked glycoproteins, releasing intact N-glycans from proteins bound for degradation. In this study, we describe the clinical spectrum of NGLY1 deficiency (NGLY1-CDDG).Methods:Prospective natural history protocol.Results:In 12 individuals ages 2 to 21 years with confirmed, biallelic, pathogenic NGLY1 mutations, we identified previously unreported clinical features, including optic atrophy and retinal pigmentary changes/cone dystrophy, delayed bone age, joint hypermobility, and lower than predicted resting energy expenditure. Novel laboratory findings include low cerebral spinal fluid (CSF) total protein and albumin and unusually high antibody titers toward rubella and/or rubeola following vaccination. We also confirmed and further quantified previously reported findings noting that decreased tear production, transient transaminitis, small feet, a complex hyperkinetic movement disorder, and varying degrees of global developmental delay with relatively preserved socialization are the most consistent features.Conclusion:Our prospective phenotyping expands the clinical spectrum of NGLY1-CDDG, offers prognostic information, and provides baseline data for evaluating therapeutic interventions.Genet Med19 2, 160–168.

genetics & heredity
Expanding the phenotype and metabolic basis of ATP6AP2-congenital disorder of glycosylation in a Chinese patient with a novel variant c.185G>A (p.Gly62Glu)

Yuan Fang,Yi-Zhen Wang,Lian Chen,Xin-Bao Xie

DOI: https://doi.org/10.3389/fgene.2023.1264237

IF: 3.7

2023-11-22

Frontiers in Genetics

Abstract:Background: A rare X-linked hereditary condition known as ATP6AP2-congenital disorder of glycosylation (ATP6AP2-CDG) is caused by pathogenic variants in ATP6AP2 , resulting in autophagic misregulation with reduced siganling of mammalian target of rapamycin (mTOR) that clinically presents with aberrant protein glycosylation, hepatosteatosis, immunodeficiency, cutis laxa, and psychomotor dysfunction. To date, only two missense mutations have been reported in three patients from two unrelated families. Methods: In order to extend the profiles of phenotype and genotype associated with ATP6AP2-CDG, we assessed the clinical history, whole exome sequencing (WES), and liver histology as well as immunohistochemistry in a Chinese patient, and performed quantitative real-time polymerase chain reaction (qRT-PCR), Western blotting and untargeted metabolomics in genetic exogenously constructed cells. Results: The 11-month-old Chinese boy presented with recurrent jaundice, cutis laxa, cirrhosis, growth retardation, coagulopathy, anemia, and cardiomegaly, and underwent liver transplantation. A novel mutation, c.185G>A (p.Gly62Glu), was identified in exon 3 of ATP6AP2 . The expression of ATP6AP2 was observed to remain unchanged in the liver sample of the patient as well as in HEK293T cells harboring the p.Gly62Glu. This missense mutation was found to dysregulate autophagy and mTOR signaling. Moreover, metabolomics analysis revealed that the exogenously introduced Gly62Glu mutant resulted in the downregulation of numerous metabolites involved in lipid metabolism pathway. Conclusion: This study may enable a more detailed exploration of its precise pathogenesis and potential therapeutic interventions.

genetics & heredity
Identification and characterization of a new variation in DPM2 gene in two Chinese siblings with mild intellectual impairment

Peiwei Zhao,Yanqiu Hu,Juan Hu,Cheng Li,Yufeng Huang,Lei Zhang,Sukun Luo,Hongmin Zhu,Jun Jiang,Xuelian He

DOI: https://doi.org/10.3389/fgene.2023.930692

IF: 3.7

2023-04-20

Frontiers in Genetics

Abstract:Introduction: Congenital disorders of glycosylation (CDGs) are a genetically heterogeneous group of metabolic disorders caused by abnormal protein or lpid glycosylation. DPM2 is one subunit of a heterotrimeric complex for dolichol-phosphatemannose synthase (DPMS), a key enzyme in glycosylation, and only four patients with DPM2-CDG have been reported. Methods: Whole-exome sequencing (WES) was performed in a Chinese family having two siblings with a mild form of DPM2-CDG with developmental delay, mild intellectual disability, hypotonia, and increased serum creatine kinase. Sanger sequencing was used to validate the variants identified in the siblings and their parents. In vitro functional study was performed. Results: A homozygous mutation, c.197G>A (p.Gly66Glu) in exon 4 of DPM2 (NM_003863) was identified by whole exome sequencing (WES). In vitro functional analysis demonstrated that this variant increased the expression level of DPM2 protein and western blot revealed a significant decrease in ICAM1, a universal biomarker for hypoglycosylation in patients with CDG, suggesting abnormal N-linked glycosylation. We also reviewed the 4 previously reported patients carrying homozygous or compound heterozygous variants of DMP2 gene, and found that patients with variants within the region encoding the first domain had more severe clinical symptoms than those with variants within the second domain. However, the actual genotype-phenotype relationship needs more study. Discussion: Overall, our study broadens the variant spectrum of DPM2 gene, attempts to explain the different phenotypes in patients with different DPM2 variants, and emphasizes the need of further functional studies to understand the underlying pathophysiology of the phenotypic heterogeneity.

genetics & heredity
Review and metabolomic profiling of unsolved case reveals newly reported autosomal dominant congenital disorder of glycosylation, type Iw formerly thought to only be an autosomal recessive condition

Kimberly M. Ezell,Yutaka Furuta,Devin Oglesbee,Eniko K. Pivnick,David Rinker,Jonathan H. Sheehan,Rory J. Tinker,Rizwan Hamid,Joy D. Cogan,Lynette Rives,Serena Neumann,Brian Corner,Mary Koziura,John A. Phillips

DOI: https://doi.org/10.1016/j.ymgmr.2024.101145

IF: 2.082

2024-10-06

Molecular Genetics and Metabolism Reports

Abstract:Autosomal dominant congenital disorder of glycosylation (CDG) type Iw (OMIM# 619714 ) is caused by a heterozygous mutation in the STT3A gene. Most CDGs have an autosomal recessive (AR) mode of inheritance, but several cases with an autosomal dominant (AD) form of an AR CDG have been recently identified. This report describes a 17-year-old male who was referred to the Undiagnosed Diseases Network (UDN) with a history of macrocephaly, failure to thrive, short stature, epilepsy, autism, attention-deficit/hyperactivity disorder, mild developmental delay, intermittent hypotonia, dysmorphic features, and mildly enlarged aortic root. Trio exome sequencing was negative. His biochemical workup included normal plasma amino acids, ammonia, acylcarnitine profile and urine organic and amino acids. His UDN genome sequencing (GS) identified a previously unreported de novo STT3A variant (c.1631A > G: p.Asn544Ser). This variant removes a glycosylation site and was predicted to be destabilizing by structural biology modeling. The patient was formally diagnosed by the UDN Metabolomics Core as having an abnormal transferrin profile indicative of CDG type Iw through metabolomic profiling. We report here an affected male with phenotypic, molecular, and metabolic findings consistent with CDG type Iw due to a heterozygous STT3A variant. This case highlights the importance of further testing of individuals with the phenotypic and metabolic findings of an AR disorder who are heterozygous for a single disease-causing allele and can be shown to have a new AD form of the disorder that represents clinical heterogeneity.

genetics & heredity
Congenital Disorders of Glycosylation from a Neurological Perspective

Justyna Paprocka,Aleksandra Jezela-Stanek,Anna Tylki-Szymańska,Stephanie Grunewald

DOI: https://doi.org/10.3390/brainsci11010088

IF: 3.333

2021-01-11

Brain Sciences

Abstract:Most plasma proteins, cell membrane proteins and other proteins are glycoproteins with sugar chains attached to the polypeptide-glycans. Glycosylation is the main element of the post-translational transformation of most human proteins. Since glycosylation processes are necessary for many different biological processes, patients present a diverse spectrum of phenotypes and severity of symptoms. The most frequently observed neurological symptoms in congenital disorders of glycosylation (CDG) are: epilepsy, intellectual disability, myopathies, neuropathies and stroke-like episodes. Epilepsy is seen in many CDG subtypes and particularly present in the case of mutations in the following genes: ALG13, DOLK, DPAGT1, SLC35A2, ST3GAL3, PIGA, PIGW, ST3GAL5. On brain neuroimaging, atrophic changes of the cerebellum and cerebrum are frequently seen. Brain malformations particularly in the group of dystroglycanopathies are reported. Despite the growing number of CDG patients in the world and often neurological symptoms dominating in the clinical picture, the number of performed screening tests eg transferrin isoforms is systematically decreasing as broadened genetic testing is recently more favored. The aim of the review is the summary of selected neurological symptoms in CDG described in the literature in one paper. It is especially important for pediatric neurologists not experienced in the field of metabolic medicine. It may help to facilitate the diagnosis of this expanding group of disorders. Biochemically, this paper focuses on protein glycosylation abnormalities.

neurosciences

[CONGENITAL PSEUDOEROSION OF THE CERVIX UTERI AND ITS OUTCOME].

ALG9-CDG: New Clinical Case and Review of the Literature

ALG13 X‐linked intellectual disability: New variants, glycosylation analysis, and expanded phenotypes

Identification of two novel variants in ALG11 causing congenital disorder of glycosylation

Targeted Sequencing and RNA Assay Reveal a Noncanonical JAG1 Splicing Variant Causing Alagille Syndrome.

Application of the change in partition coefficient with pH to the structure determination of alkyl substituted guanosines.

A case of fatal Type I congenital disorders of glycosylation (CDG I) associated with low dehydrodolichol diphosphate synthase (DHDDS) activity

Neurobehavioral changes following bilateral infarct in the caudate nuclei: a case report with pathological analysis

Case report: Novel genotype of ALG2-CDG and confirmation of the heptasaccharide glycan (NeuAc-Gal-GlcNAc-Man2-GlcNAc2) as a specific diagnostic biomarker

Dysregulated proteome and N‐glycoproteome in ALG1‐deficient fibroblasts

COG6-CDG: Two Novel Variants and Milder Phenotype in a Chinese Patient

Two compound heterozygous variants in the CLN8 gene are responsible for neuronal cereidolipofuscinoses disorder in a child: a case report

The phenotypic spectrum of X-linked, infantile onset ALG13-related developmental and epileptic encephalopathy

Normal transferrin glycosylation does not rule out severe ALG1 deficiency

Deficient glycan extension and endoplasmic reticulum stresses in ALG3‐CDG

X-Ray Lasers: Picosecond Soft X-Ray Laser Pulses from an Injection-Seeded Plasma Amplifier

Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation

Expanding the phenotype and metabolic basis of ATP6AP2-congenital disorder of glycosylation in a Chinese patient with a novel variant c.185G>A (p.Gly62Glu)

Identification and characterization of a new variation in DPM2 gene in two Chinese siblings with mild intellectual impairment

Review and metabolomic profiling of unsolved case reveals newly reported autosomal dominant congenital disorder of glycosylation, type Iw formerly thought to only be an autosomal recessive condition

Congenital Disorders of Glycosylation from a Neurological Perspective